Inflarx Nv (IFRX)

$1.66

+0.08

(+5.06%)▲

Live

Insights on Inflarx Nv

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 135.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 284.6%

Performance

  • $1.54
    $1.68
    $1.66
    downward going graph

    7.23%

    Downside

    Day's Volatility :8.33%

    Upside

    1.19%

    downward going graph
  • $1.14
    $4.70
    $1.66
    downward going graph

    31.33%

    Downside

    52 Weeks Volatility :75.74%

    Upside

    64.68%

    downward going graph

Returns

PeriodInflarx NvIndex (Russel 2000)
3 Months
-10.73%
0.0%
6 Months
12.06%
0.0%
1 Year
-61.93%
0.0%
3 Years
-49.52%
-22.6%

Highlights

Market Capitalization
93.0M
Book Value
$1.61
Earnings Per Share (EPS)
-0.76
Wall Street Target Price
8.04
Profit Margin
0.0%
Operating Margin TTM
-34655.19%
Return On Assets TTM
-25.25%
Return On Equity TTM
-47.58%
Revenue TTM
99.1K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-39.0M
Diluted Eps TTM
-0.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.8
EPS Estimate Next Year
-0.93
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.27

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Inflarx Nv(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 384.34%

Current $1.66
Target $8.04

Technicals Summary

Sell

Neutral

Buy

Inflarx Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inflarx Nv
Inflarx Nv
22.01%
12.06%
-61.93%
-49.52%
-95.76%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inflarx Nv
Inflarx Nv
NA
NA
NA
-0.8
-0.48
-0.25
NA
1.61
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inflarx Nv
Inflarx Nv
Buy
$93.0M
-95.76%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Suvretta Capital Management, LLC

    9.74%

  • Eversept Partners, LLC

    2.22%

  • Citigroup Inc

    2.04%

  • Morgan Stanley - Brokerage Accounts

    1.66%

  • 683 Capital Management LLC

    1.48%

  • TANG CAPITAL MANAGEMENT LLC

    1.31%

Company Information

inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe

Organization
Inflarx Nv
Employees
62
CEO
Dr. Niels C. Riedemann M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs